NCT02478866View on ClinicalTrials.gov

Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 11, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

November 30, 2017

Conditions
Solid Tumors
Interventions
DRUG

BPI-9016M

Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg，600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.

Trial Locations (2)

100021

Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing

100032

Peking Union College Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY